Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Current Oncology (Toronto, Ont.)|November 26, 2025
Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the OptionsJacob C Easaw, Howard J Lim, Hatim Karachiwala, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian PerspectiveVincent C Tam, Ravi Ramjeesingh, Ronald Burkes, et al.
American Journal of Clinical Oncology|July 14, 2015
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective StudyMaria Yi Ho, Hagen F Kennecke, Daniel J Renouf, et al.
Journal of Oncology Practice|September 22, 2010
Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based studyHoward J Lim, Sharlene Gill, Caroline Speers, et al.
American Journal of Clinical Oncology|September 2, 2020
Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma: A Population-based StudyErica S Tsang, Janine M Davies, Jonathan M Loree, et al.
World Journal of Gastroenterology|November 2, 2020
Real-world treatment attrition rates in advanced esophagogastric cancerErica S Tsang, Howard J Lim, Daniel J Renouf, et al.
Annals of Surgical Oncology|May 27, 2014
Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patientsGillian Gresham, Daniel J Renouf, Matthew Chan, et al.
Journal of Gastrointestinal Oncology|May 20, 2021
Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapySelina K Wong, Lovedeep Gondara, Daniel J Renouf, et al.
American Journal of Clinical Oncology|April 7, 2015
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOXRenata D Peixoto, Maria Ho, Daniel J Renouf, et al.
Cancer Treatment Reviews|June 19, 2023
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic reviewBrandon M Meyers, Jennifer J Knox, David M Liu, et al.
Pageof 8